New Breast Cancer Study Findings Have Been Reported by Investigators at University of Rochester (In Er-positive, Her2-negative Breast Cancers, Her2 Mrna Levels Correlate Better With Clinicopathologic Features and Oncotype Dx Recurrence Score...).

A new study conducted at the University of Rochester in New York has explored the relationship between HER2 immunohistochemistry (IHC) scores and mRNA levels in estrogen receptor (ER)-positive, HER2-negative breast cancers (BCs). The study found that HER2 mRNA levels correlated better with clinicopathologic features and recurrence risk than HER2 IHC scores. The researchers suggest that HER2 mRNA-detecting methods could potentially serve as a quantitative and reliable method for identifying a biologically meaningful group of HER2-low BCs. Further study is needed to determine whether HER2 mRNA levels could be more reliable than IHC for identifying patients who will benefit from trastuzumab deruxtecan. [Extracted from the article]